Canopy Growth posts mixed Q3 results, narrower loss amid ongoing cost cuts

Canopy Growth reported fiscal Q3 net revenue of C$74.5m versus a C$70.5m consensus, with net loss narrowing 49% year-over-year and a loss per share of C$0.18 (worse than the C$0.08 expected). Adjusted EBITDA loss narrowed 17% as SG&A declined and the company said it has achieved C$29m in annualized cost savings since March 2025; cannabis net revenue was C$52m (+4% y/y) driven by Canadian medical (+15% to C$23m) and adult-use (+8% to C$23m), while international cannabis fell 31% y/y (but rose 22% sequentially) due to European supply-chain issues. Storz & Bickel revenue was C$23m (up 45% sequentially, down 9% y/y), consolidated gross margin slipped to 29% from 32%, and the acquisition of MTL Cannabis is expected to close this quarter to bolster the global platform.

Analysis

Market structure: Canopy (CGC) shows Canada-led stabilization (Q3 revenue C$74.5m, cannabis C$52m) while international weakness (−31% YoY) compresses consolidated gross margin to 29% from 32%. Winners are domestically-focused producers, vape brand holders (Storz & Bickel sequential +45%) and acquirers of scale; losers are EU-dependent suppliers and MSOs with large European exposure. Cross-asset: a prolonged international slump would pressure credit spreads on weed issuers and keep equity implied vols elevated; CAD sensitivity is modest but a stronger CAD supports CGC reported CAD-denominated metrics versus USD peers.

Risk assessment: Tail risks include EU regulatory/GMP stoppages, a failed or dilutive MTL integration, and hostile provincial pricing interventions — each could swing EBITDA by >C$30–50m over 12 months. Time horizons: immediate (days) volatility around MTL-close rumors; short-term (0–3 months) execution on C$29m annualized cost cuts and EU shipment normalization; long-term (6–18 months) depends on realization of synergy and margin recovery. Hidden dependencies: insured-patient growth is payor-dependent and can reverse quickly; currency moves (EUR/CAD) materially alter reported international revenue. Key catalysts: MTL closing in the coming quarter, EU shipment cadence over next 60–90 days, next quarterly release ~90 days.

Trade implications: Direct: size a tactical long in CGC (2–3% net exposure) if price retraces ≥5% from post-report levels, targeting 3–6 month horizon to capture cost-savings ramp and MTL close. Options: buy a 90-day call spread (long ~20% OTM, short ~40% OTM) sized to 1–2% portfolio risk to cap premium while betting on a positive near-term catalyst. Pair: long CGC / short TLRY equal notional for 3–6 months to express preference for Canada-anchored execution over EU-exposed peers; target relative outperformance of 10–20%.

Contrarian angles: Consensus underweights the C$29m annualized SG&A savings — if sustained, that alone can move adj. EBITDA toward breakeven within 12–18 months and is likely underpriced. The per-share miss masks operational improvement; an overreaction would present a buy-on-weakness opportunity if MTL closes without material dilution. Historical parallels: post-cut restructurings in Canadian cannabis have produced 30–70% recoveries over 6–12 months when international logistics normalize. Watch for unintended consequences: MTL could add regulatory exposure or inventory write-down risk; exit if combined leverage increases EBITDA interest cover risk by >25% versus current levels.

Key Decisions for Investors

• Establish a tactical 2–3% long position in CGC on a pullback of ≥5% from current levels within the next 30 days, target 3–6 month hold; set a hard stop-loss at −20% and a take-profit at +50% (reflects optionality from MTL and C$29m cost saves).
• Buy a 90-day call spread on CGC sized to 1–2% portfolio risk: long call ~20% OTM / short call ~40% OTM to capture MTL-close and EU shipment normalization while limiting premium outlay; roll if MTL not closed within 90 days.
• Execute a pair trade: long CGC / short TLRY equal notional for 3–6 months to express relative preference for Canada-driven execution; close if spread does not compress by at least 10% in 90 days or if TLRY reports material EU recovery.
• Reduce exposure to EU-exposed cannabis names (e.g., TLRY, CRON) by 25% of current weight and redeploy 1–2% into CGC or into cash/defensive consumer staples if CGC fails to close MTL in 60 days; reassess after next quarterly report.